Literature DB >> 23039638

Motion mitigation in intensity modulated particle therapy by internal target volumes covering range changes.

Christian Graeff1, Marco Durante, Christoph Bert.   

Abstract

PURPOSE: Particle therapy offers benefits over conventional photon therapy but also introduces sensitivity to changes in the water-equivalent path length (WEPL) in case of target motion, e.g., breathing. Target motion can be addressed by the internal target volume (ITV) approach, defined as the CTV plus target movement. In photon therapy, the ITV can be constructed as the geometric union of CTVs in all motion states (GEO-ITV) of a 4D-CT, but this does not account for WEPL-changes. An ITV including WEPL-changes can be defined as the union of all CTVs transformed to a WEPL-equivalent axis along beam's eye view. The resulting WEPL-ITV is field-specific and thus unsuitable for intensity modulated particle therapy (IMPT). The purpose of this study was an IMPT-compatible ITV by splitting geometrical motion and field-specific WEPL changes, following ICRU 78 recommendations.
METHODS: For all fields, the GEO-ITV was used as a common target. This identical geometry for all fields was mapped to an enlarged WEPL extent with a field-specific transformation. As the dose distribution is determined by the WEPL, this is sufficient to achieve equivalent dose coverage as for a geometrically enlarged target volume. The WEPL enlargement is only visible to the specific field and therefore does not increase the target volume of other fields. This avoids unnecessary lateral field extensions, reducing the dose to normal tissue. Homogeneous dose coverage in IMPT is achieved only if the inhomogeneous doses from the individual fields match up during delivery. As the course of the WEPL within each motion phase differs, this cannot be guaranteed by optimizing the fields only in the reference phase. The WEPL-ITV for the reference phase can be amended by CTVs from a subset of motion phases (4D-WEPL-ITV). Here, end-exhale as the reference phase was combined with end-inhale to cover the whole motion range. The GEO-ITV, WEPL-ITV, and 4D-WEPL-ITV were applied in an IMPT simulation of a lung cancer patient case using a four-field geometry and the heart as an OAR. A static plan of the CTV in end-exhale was computed for reference. The CTV was moving approximately 20 mm in SI and was partly overlapping the heart. For a single fraction a target dose of 17.7 GyE was prescribed, with a 50% maximum dose for the heart.
RESULTS: With 21 rescans to counter interplay, the homogeneity (D5-D95) was 17.0%, 9.0%, 6.0%, and 3.5% for the GEO-ITV, WEPL-ITV, 4D-WEPL-ITV, and a 3D CTV plan computed for reference, respectively. Due to the overlap, the 50% maximum dose was violated by all plans, with V50 of 3.8%, 3.5%, 3.7%, and 2.0% for the four plans.
CONCLUSIONS: A 4D-WEPL-ITV method was developed that is suitable for IMPT, covers range changes, and drastically improves dose homogeneity in the target without increasing the OAR dose.

Entities:  

Mesh:

Year:  2012        PMID: 23039638     DOI: 10.1118/1.4749964

Source DB:  PubMed          Journal:  Med Phys        ISSN: 0094-2405            Impact factor:   4.071


  27 in total

Review 1.  Individualized radiotherapy by combining high-end irradiation and magnetic resonance imaging.

Authors:  Stephanie E Combs; Fridtjof Nüsslin; Jan J Wilkens
Journal:  Strahlenther Onkol       Date:  2016-02-06       Impact factor: 3.621

2.  Effect of secondary particles on image quality of dynamic flat panels in carbon ion scanning beam treatment.

Authors:  S Mori; S Amano; T Furukawa; T Shirai; K Noda
Journal:  Br J Radiol       Date:  2014-12-23       Impact factor: 3.039

3.  Dose escalation study with respiratory-gated carbon-ion scanning radiotherapy using a simultaneous integrated boost for pancreatic cancer: simulation with four-dimensional computed tomography.

Authors:  Shohei Kawashiro; Shinichiro Mori; Shigeru Yamada; Kentaro Miki; Kenji Nemoto; Hiroshi Tsuji; Tadashi Kamada
Journal:  Br J Radiol       Date:  2017-02-09       Impact factor: 3.039

4.  Implementation of a target volume design function for intrafractional range variation in a particle beam treatment planning system.

Authors:  S Mori; T Inaniwa; K Miki; T Shirai; K Noda
Journal:  Br J Radiol       Date:  2014-08-29       Impact factor: 3.039

5.  Robust optimization in IMPT using quadratic objective functions to account for the minimum MU constraint.

Authors:  Jie Shan; Yu An; Martin Bues; Steven E Schild; Wei Liu
Journal:  Med Phys       Date:  2017-12-05       Impact factor: 4.071

6.  Density overwrites of internal tumor volumes in intensity modulated proton therapy plans for mobile lung tumors.

Authors:  Pablo Botas; Clemens Grassberger; Gregory Sharp; Harald Paganetti
Journal:  Phys Med Biol       Date:  2018-01-30       Impact factor: 3.609

7.  Four-dimensional Monte Carlo simulations demonstrating how the extent of intensity-modulation impacts motion effects in proton therapy lung treatments.

Authors:  Stephen Dowdell; Clemens Grassberger; Harald Paganetti
Journal:  Med Phys       Date:  2013-12       Impact factor: 4.071

8.  Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer.

Authors:  Chenbin Liu; Steven E Schild; Joe Y Chang; Zhongxing Liao; Shawn Korte; Jiajian Shen; Xiaoning Ding; Yanle Hu; Yixiu Kang; Sameer R Keole; Terence T Sio; William W Wong; Narayan Sahoo; Martin Bues; Wei Liu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-02-14       Impact factor: 7.038

9.  Scanned ion beam therapy for prostate carcinoma: Comparison of single plan treatment and daily plan-adapted treatment.

Authors:  Sebastian Hild; Christian Graeff; Antoni Rucinski; Klemens Zink; Gregor Habl; Marco Durante; Klaus Herfarth; Christoph Bert
Journal:  Strahlenther Onkol       Date:  2015-11-27       Impact factor: 3.621

Review 10.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.